Robeco Institutional Asset Management B.V. Has $114,039,000 Stake in AbbVie Inc. (ABBV)
Robeco Institutional Asset Management B.V. reduced its position in AbbVie Inc. (NYSE:ABBV) by 1.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,842,016 shares of the company’s stock after selling 21,881 shares during the period. AbbVie comprises approximately 0.9% of Robeco Institutional Asset Management B.V.’s portfolio, making the stock its 18th largest position. Robeco Institutional Asset Management B.V. owned approximately 0.11% of AbbVie worth $114,039,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in ABBV. Regent Investment Management LLC boosted its position in AbbVie by 0.3% in the first quarter. Regent Investment Management LLC now owns 11,929 shares of the company’s stock valued at $681,000 after buying an additional 30 shares in the last quarter. Ronna Sue Cohen boosted its position in AbbVie by 0.8% in the first quarter. Ronna Sue Cohen now owns 27,401 shares of the company’s stock valued at $1,565,000 after buying an additional 214 shares in the last quarter. City Holding Co. boosted its position in AbbVie by 5.4% in the first quarter. City Holding Co. now owns 36,802 shares of the company’s stock valued at $2,102,000 after buying an additional 1,900 shares in the last quarter. Raymond James Trust N.A. boosted its position in AbbVie by 12.9% in the first quarter. Raymond James Trust N.A. now owns 132,760 shares of the company’s stock valued at $7,582,000 after buying an additional 15,201 shares in the last quarter. Finally, Stokes & Hubbell Capital Management LLC boosted its position in AbbVie by 2.2% in the first quarter. Stokes & Hubbell Capital Management LLC now owns 34,853 shares of the company’s stock valued at $1,991,000 after buying an additional 742 shares in the last quarter. 68.36% of the stock is owned by institutional investors.
AbbVie Inc. (NYSE:ABBV) traded up 0.60% on Monday, reaching $63.31. The company’s stock had a trading volume of 3,135,309 shares. The firm’s 50 day moving average is $64.13 and its 200-day moving average is $62.54. The firm has a market cap of $103.10 billion, a P/E ratio of 18.26 and a beta of 1.50. AbbVie Inc. has a 12 month low of $45.45 and a 12 month high of $68.12.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.06. The firm earned $6.43 billion during the quarter, compared to the consensus estimate of $6.20 billion. AbbVie had a net margin of 23.11% and a return on equity of 161.46%. The business’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same period last year, the business posted $1.08 earnings per share. On average, equities research analysts anticipate that AbbVie Inc. will post $4.81 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Shareholders of record on Friday, October 14th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Wednesday, October 12th. This represents a $2.28 annualized dividend and a yield of 3.60%. AbbVie’s dividend payout ratio (DPR) is presently 65.71%.
ABBV has been the subject of several research analyst reports. Vetr raised AbbVie from a “buy” rating to a “strong-buy” rating and set a $68.08 price objective for the company in a research report on Monday, June 13th. Zacks Investment Research raised AbbVie from a “sell” rating to a “hold” rating in a report on Wednesday, June 29th. Credit Suisse Group AG reaffirmed an “outperform” rating and issued a $67.00 price target on shares of AbbVie in a report on Wednesday, June 29th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $66.00 price target on shares of AbbVie in a report on Friday, July 29th. Finally, Barclays PLC reaffirmed an “equal weight” rating and issued a $68.00 price target on shares of AbbVie in a report on Tuesday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. AbbVie presently has a consensus rating of “Buy” and a consensus target price of $70.68.
In other AbbVie news, insider Laura J. Schumacher sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $65.00, for a total transaction of $3,250,000.00. Following the completion of the sale, the insider now directly owns 144,138 shares in the company, valued at $9,368,970. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.11% of the company’s stock.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.
Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.